Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 clinical trial were presented.

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...

The study measured the estimated glomerular filtration rate to gauge kidney function. Credit: Peakstock / Shutterstock.com. Maze Therapeutics has shared positive outcomes from the randomised Phase I ...

The RTSM component of the platform is used by CROs, sponsors, and clinical trial sites to randomise participants. Credit: create jobs 51 / Shutterstock.com. Amgen has entered a partnership to use ...

Schizophrenia is known for its severe impact on mental health, with patients often experiencing a range of debilitating symptoms. Credit: sulit.photos / Shutterstock.com. UK-based Monument ...